Francesca Alvarez-Calderon

9PUBLICATIONS
41CO-AUTHORS
Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)BiofabricationTumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Sep 02, 2026
PTPN2 Deletion Enhances CAR-T Effector Function and CNS Trafficking in a Non-Human Primate Model.

|Jul 17, 2026
Allogeneic HSCT outcomes and impact of defibrotide prophylaxis on SOS after inotuzumab in pediatric B-ALL.

|Sep 26, 2025
PTPN2-KO CAR-T Cells Demonstrate Enhanced Effector Function, CNS Infiltration, and Toxicity in a Non-Human Primate CAR-T Model.

Francesca Alvarez Calderon, Ryan A Fleming, Marlana Winschel

|Oct 16, 2024
Human OX40L-CAR-Tregs target activated antigen-presenting cells and control T cell alloreactivity.

Xianliang Rui, Francesca Alvarez Calderon, Holly Wobma

|Apr 01, 2024
B-cell-directed CAR T-cell therapy activates CD8+ cytotoxic CARneg bystander T cells in patients and nonhuman primates.

James Kaminski, Ryan A Fleming, Francesca Alvarez-Calderon

|Mar 06, 2024
Alloengraftment without significant toxicity or GVHD in CD45 antibody-drug conjugate-conditioned Fanconi anemia mice.

Asim Saha, Rahul Palchaudhuri, Leanne Lanieri

Pageof 2

Frequent Collaborators

4 joint publications

Lev Gorfinkel

4 joint publications

Victor Tkachev

3 joint publications

James Kaminski

3 joint publications

Ulrike Gerdemann